

CITATION REPORT

List of articles citing

Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus

DOI: 10.1177/0961203307078579

Lupus, 2007, 16, 401-9.

Source: <https://exaly.com/paper-pdf/41547606/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
157	Development of risk profiles for systemic lupus erythematosus. 2007 , 2, 507-514		
156	Primary prevention of systemic lupus erythematosus. 2008 , 4, 576-7		10
155	Hydroxychloroquine: the cornerstone of lupus therapy. <i>Lupus</i> , 2008 , 17, 271-3	2.6	51
154	Bibliography. Current world literature. Systemic lupus erythematosus and Sjögren's syndrome. 2008 , 20, 631-2		
153	Clinically relevant information about cutaneous lupus erythematosus. 2009 , 145, 316-9		15
152	Anti-malarials and Lupus in West Africa use and lupus in Africans. <i>Lupus</i> , 2009 , 18, 193-5	2.6	7
151	Undifferentiated connective tissue disease: a seven-center cross-sectional study of 184 patients. <i>Clinical Rheumatology</i> , 2009 , 28, 915-21	3.9	49
150	[Antimalarials. A treatment option for every lupus patient!?.] 2009 , 68, 584, 586-90		4
149	SLE diagnosis and treatment: when early is early. 2010 , 10, 55-60		111
148	Why all systemic lupus erythematosus patients should be given hydroxychloroquine treatment?. 2010 , 77, 4-5		26
147	Pourquoi faut-il traiter tous les patients atteints de lupus systémique par hydroxychloroquine ?. 2010 , 77, 4-6		
146	Therapy: Hydroxychloroquine in SLE: old drug, new perspectives. <i>Nature Reviews Rheumatology</i> , 2010 , 6, 10-1	8.1	31
145	Ro60-associated single-stranded RNA links inflammation with fetal cardiac fibrosis via ligation of TLRs: a novel pathway to autoimmune-associated heart block. 2010 , 184, 2148-55		76
144	Correction. 2010 , 69, 28-28		1
143	A new role for antimalarials in systemic lupus erythematosus treatment. 2010 , 5, 299-312		1
142	Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. 2010 , 69, 20-8		645
141	Preclinical rheumatoid arthritis: identification, evaluation, and future directions for investigation. 2010 , 36, 213-41		106

140	The role of antimalarial agents in the treatment of SLE and lupus nephritis. 2011 , 7, 718-29		166
139	Implications of long-term medication of oral steroids and antimalarial drugs in primary Sjögren's syndrome. 2011 , 11, 2125-9		5
138	Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy. 2011 , 10, 705-14		61
137	Antimalarials and SLE. 2011 , 1061-1081		0
136	Antimaláricos e perfil lipídico em pacientes com lúpus eritematoso sistêmico. 2011 , 51, 385-387		3
135	Practice Gaps. Optimizing antimalarial therapy for cutaneous lupus erythematosus: comment on "Response to antimalarial agents in cutaneous lupus erythematosus". 2011 , 147, 1267-8		2
134	Anti-malarials exert a protective effect while Mestizo patients are at increased risk of developing SLE renal disease: data from a Latin-American cohort. <i>Rheumatology</i> , 2012 , 51, 1293-8	3.9	39
133	Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects. 2012 , 42, 968-78		73
132	Autoantibody profiling to follow evolution of lupus syndromes. 2012 , 14, R174		56
131	Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus. 2012 , 14, R155		148
130	New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. <i>Nature Reviews Rheumatology</i> , 2012 , 8, 522-33	8.1	145
129	Geographical differences in autoantibodies and anti-infectious agents antibodies among healthy adults. 2012 , 42, 154-63		45
128	Determining risk factors for developing systemic lupus erythematosus in patients with discoid lupus erythematosus. 2012 , 166, 29-35		70
127	Treatment of systemic lupus erythematosus: new advances in targeted therapy. 2012 , 1247, 138-52		31
126	Insights into the pathophysiology of the antiphospholipid syndrome provided by atomic force microscopy. 2012 , 43, 851-62		7
125	[Early lupus erythematosus]. 2013 , 72, 948-53		1
124	Is there an effective treatment for late-onset systemic lupus erythematosus?. 2013 , 9, 437-450		
123	Antimalarial Medications. 2013 , 601-608		3

122	Multifaceted effects of hydroxychloroquine in human disease. <i>Seminars in Arthritis and Rheumatism</i> , 2013 , 43, 264-72	5.3	88
121	Children and adolescents with SLE: not just little adults. <i>Lupus</i> , 2013 , 22, 1309-19	2.6	30
120	The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2013 , 40, 831-41	4.1	79
119	Systemic symptoms in the progression of cutaneous to systemic lupus erythematosus. 2014 , 150, 291-6		61
118	Understanding how cutaneous lupus erythematosus progresses to systemic lupus erythematosus. 2014 , 150, 296		10
117	Pathogenesis and prevention of rheumatic disease: focus on preclinical RA and SLE. <i>Nature Reviews Rheumatology</i> , 2014 , 10, 212-28	8.1	93
116	Development of SLE among "potential SLE" patients seen in consultation: long-term follow-up. 2014 , 68, 1508-13		33
115	Severe Skin Diseases in Children. 2014 ,		
114	Prevention of rheumatic diseases: strategies, caveats, and future directions. 2014 , 40, 771-85		17
113	Preclinical systemic lupus erythematosus. 2014 , 40, 621-35		28
112	Immunologic derangement preceding clinical autoimmunity. <i>Lupus</i> , 2014 , 23, 1305-8	2.6	4
111	Hydroxychloroquine: a multifaceted treatment in lupus. 2014 , 43, e167-80		101
110	Early treatment with hydroxychloroquine prevents the development of endothelial dysfunction in a murine model of systemic lupus erythematosus. 2015 , 17, 277		46
109	Preclinical lupus. 2015 , 27, 433-9		23
108	Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome. 2015 , 14, 358-62		84
107	Malaria and Systemic Lupus Erythematosus: Complex Interactions and Reciprocal Influences. 2015 , 657-668		
106	The natural history of pediatric-onset discoid lupus erythematosus. 2015 , 72, 628-33		35
105	Current and future treatment options for cutaneous lupus erythematosus. 2015 , 3, 777-786		

104	A highlight from the LUPUS 2014 meeting: eight great ideas. <i>Lupus Science and Medicine</i> , 2015 , 2, e0000876	10
103	The need for preclinical biomarkers in systemic autoimmune rheumatic diseases. <i>Journal of Rheumatology</i> , 2015 , 42, 152-4	4-1 5
102	Incomplete Lupus. 2016 , 463-466	
101	Value of Antimalarial Drugs in the Treatment of Lupus. 2016 , 515-520	
100	Immunomodulators in SLE: Clinical evidence and immunologic actions. 2016 , 74, 73-84	54
99	Preclinical disease and preventive strategies in IBD: perspectives, challenges and opportunities. 2016 , 65, 1061-9	42
98	Primary cicatricial alopecia: Lymphocytic primary cicatricial alopecias, including chronic cutaneous lupus erythematosus, lichen planopilaris, frontal fibrosing alopecia, and Graham-Little syndrome. 2016 , 75, 1081-1099	71
97	Dysregulation of innate and adaptive serum mediators precedes systemic lupus erythematosus classification and improves prognostic accuracy of autoantibodies. 2016 , 74, 182-193	100
96	Preventing the development of SLE: identifying risk factors and proposing pathways for clinical care. <i>Lupus</i> , 2016 , 25, 838-49	2.6 29
95	Cutaneous Lupus Erythematosus: An Update on Pathogenesis, Diagnosis and Treatment. 2016 , 17, 135-46	62
94	Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification. 2016 , 75, 2014-2021	132
93	Systemic lupus erythematosus: An update for ophthalmologists. 2016 , 61, 65-82	20
92	Clinical characteristics during diagnosis of a prospective cohort of patients with systemic lupus erythematosus treated in Spanish Departments of Internal Medicine: The RELES study. 2017 , 217, 7-14	2
91	Factors predictive of high disease activity early in the course of SLE in patients from a Latin-American cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2017 , 47, 199-203	5-3 5
90	Clinical and Serologic Features in Patients With Incomplete Lupus Classification Versus Systemic Lupus Erythematosus Patients and Controls. 2017 , 69, 1780-1788	27
89	Clinical characteristics during diagnosis of a prospective cohort of patients with systemic lupus erythematosus treated in Spanish Departments of Internal Medicine: The RELES study. 2017 , 217, 7-14	
88	Systemic manifestations of primary Sjögren's syndrome in the NOD.B10Sn-H2/J mouse model. 2017 , 183, 225-232	16
87	Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus. <i>Rheumatology</i> , 2017 , 56, i100-i113	3-9 27

86	Hydroxychloroquine-Induced Erythema Multiforme. <i>Journal of Clinical Rheumatology</i> , 2017 , 23, 127-128	1.1	11
85	Updated recommendations on the use of hydroxychloroquine in dermatologic practice. 2017 , 76, 1176-1182		29
84	Not Just Skin Deep: Systemic Disease Involvement in Patients With Cutaneous Lupus. 2017 , 18, S69-S74		6
83	Antimalarials in cutaneous lupus erythematosus subtypes. 2017 , 177, 14-15		
82	Systemic lupus erythematosus: still a challenge for physicians. 2017 , 281, 52-64		49
81	Discerning Risk of Disease Transition in Relatives of Systemic Lupus Erythematosus Patients Utilizing Soluble Mediators and Clinical Features. 2017 , 69, 630-642		37
80	Autoantibodies persist in relatives to systemic lupus erythematosus patients during 12 years follow-up. <i>Lupus</i> , 2017 , 26, 723-728	2.6	2
79	Juvenile-onset systemic lupus erythematosus (jSLE) - Pathophysiological concepts and treatment options. <i>Best Practice and Research in Clinical Rheumatology</i> , 2017 , 31, 488-504	5.3	31
78	Cutaneous lupus erythematosus: Reflecting on practice-changing observations over the past 50 years. 2018 , 36, 442-449		6
77	Arthritis and use of hydroxychloroquine associated with a decreased risk of macrophage activation syndrome among adult patients hospitalized with systemic lupus erythematosus. <i>Lupus</i> , 2018 , 27, 1065-1071	2.6	9
76	Systemic Therapies for Scarring and Non-scarring Alopecia. 2018 , 495-515		1
75	Natural History and Predictors of Progression to Sjögren's Syndrome Among Participants of the Sjögren's International Collaborative Clinical Alliance Registry. 2018 , 70, 284-294		27
74	AB0504 Efficacy of prolonged maintenance monotherapy with rituximab in patients with primary sjögren's syndrome: three-year follow-up. 2018 ,		
73	Study of Anti-Malarials in Incomplete Lupus Erythematosus (SMILE): study protocol for a randomized controlled trial. 2018 , 19, 694		13
72	Incremental direct medical costs of systemic lupus erythematosus patients in the years preceding diagnosis: A general population-based study. <i>Lupus</i> , 2018 , 27, 1247-1258	2.6	7
71	Distinct Hyperkeratotic Lesions on Acral Skin and Lips: A Quiz. 2018 , 98, 475-476		
70	Antimalarials - are they effective and safe in rheumatic diseases?. 2018 , 56, 164-173		51
69	Preclinical and early systemic lupus erythematosus. <i>Best Practice and Research in Clinical Rheumatology</i> , 2019 , 33, 101422	5.3	9

68	Lupus: the new epidemic. <i>Lupus</i> , 2019 , 28, 1031-1050	2.6	11
67	A review of the evidence and cost of therapies for cutaneous lupus erythematosus. <i>Lupus</i> , 2019 , 28, 799-805		1
66	Practice-based differences in paediatric discoid lupus erythematosus. 2019 , 181, 805-810		7
65	Assessment of Antimalarial Therapy in Patients Who Are Hypersensitive to Hydroxychloroquine. 2019 , 155, 491-493		2
64	Interferon score is increased in incomplete systemic lupus erythematosus and correlates with myxovirus-resistance protein A in blood and skin. 2019 , 21, 260		18
63	Machine learning applied to whole-blood RNA-sequencing data uncovers distinct subsets of patients with systemic lupus erythematosus. 2019 , 8, e01093		22
62	Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy. 2020 , 72, 448-453		50
61	Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology-Classified Systemic Lupus Erythematosus. 2020 , 72, 78-88		21
60	Hydroxychloroquine is associated with a lower risk of polyautoimmunity: data from the RELESSER Registry. <i>Rheumatology</i> , 2020 , 59, 2043-2051	3.9	2
59	New insights into the progression from cutaneous lupus to systemic lupus erythematosus. <i>Expert Review of Clinical Immunology</i> , 2020 , 16, 829-837	5.1	5
58	A three-arm, multicenter, open-label randomized controlled trial of hydroxychloroquine and low-dose prednisone to treat recurrent pregnancy loss in women with undifferentiated connective tissue diseases: protocol for the Immunosuppressant regimens for LIving Fetuses (ILIFE) trial. 2020 , 21, 771		7
57	A Sensitive and Optimized HPLC-FLD Method for the Simultaneous Quantification of Hydroxychloroquine and Its Two Metabolites in Blood of Systemic Lupus Erythematosus Patients. <i>Journal of Chromatographic Science</i> , 2020 , 58, 600-605	1.4	3
56	Toward better outcomes in Sjögren's syndrome: The promise of a stratified medicine approach. <i>Best Practice and Research in Clinical Rheumatology</i> , 2020 , 34, 101475	5.3	8
55	Incomplete lupus syndromes. 2021 , 521-526		
54	Value of antimalarial drugs in the treatment of lupus. 2021 , 591-595		1
53	Antimalarial Agents. 2021 , 234-244.e4		1
52	Hydroxychloroquine Suppresses Interferon-inducible Genes and B Cell Activating Factor in Patients With Incomplete and New-onset Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2021 , 48, 847-851	4.1	6
51	The effect of hydroxychloroquine on platelet activation in model experiments. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 52, 674-679	5.1	1

50	From incomplete to complete systemic lupus erythematosus; A review of the predictive serological immune markers. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 43-48	5.3	7
49	Post-COVID-19 arthritis: a case report and literature review. <i>Clinical Rheumatology</i> , 2021 , 40, 3357-3362	3.9	28
48	Hydroxychloroquine: An Old Drug With New Tricks. <i>Journal of Rheumatology</i> , 2021 , 48, 796-798	4.1	0
47	The Psychosocial Impact of Undifferentiated Connective Tissue Disease on Patient Health and Well-Being: A Qualitative Study. <i>Journal of Clinical Rheumatology</i> , 2021 ,	1.1	
46	Measuring IFN activity in suspected SLE: a valuable step?. <i>Expert Review of Clinical Immunology</i> , 2021 , 17, 545-548	5.1	1
45	Serological abnormalities that predict progression to systemic autoimmune rheumatic diseases in antinuclear antibody positive individuals. <i>Rheumatology</i> , 2021 ,	3.9	2
44	Antimalarial drugs-are they beneficial in rheumatic and viral diseases?-considerations in COVID-19 pandemic. <i>Clinical Rheumatology</i> , 2021 , 1	3.9	3
43	Novel Therapeutic Interventions in Systemic Lupus Erythematosus.		
42	Precision medicine as an approach to autoimmune diseases. 2021 , 39-63		1
41	Preclinical features of lupus. 2015 , 1026-1031		2
40	The female-biased factor VGLL3 drives cutaneous and systemic autoimmunity. <i>JCI Insight</i> , 2019 , 4,	9.9	28
39	The role of autoantibodies in the early diagnosis of systemic immunoinflammatory rheumatic diseases. <i>Sovremennaya Revmatologiya</i> , 2019 , 13, 5-10	0.7	4
38	Hydroxychloroquine in rheumatic autoimmune disorders and beyond. <i>EMBO Molecular Medicine</i> , 2020 , 12, e12476	12	29
37	Dermatologists' Adherence to the Latest Recommendations for Screening of Hydroxychloroquine Retinopathy in Saudi Arabia: Cross-Sectional Study. <i>Interactive Journal of Medical Research</i> , 2019 , 8, e15218	2.1	2
36	ANA-positive primary immune thrombocytopaenia: a different clinical entity with increased risk of connective tissue diseases. <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	2
35	Incomplete Lupus Erythematosus. 2011 , 707-717		
34	Connective Tissue Disease. 2014 , 91-122		
33	Machine learning applied to whole-blood RNA-sequencing data uncovers distinct subsets of patients with systemic lupus erythematosus.		

32	Antipalúdicos de síntesis en dermatología. <i>EMC - Dermatología</i> , 2020 , 54, 1-11	0.1	
31	Epidemiology and clinical characteristics of systemic sclerosis overlap syndrome (SSc-OS), and the factors significantly associated with SSc-OS in Thai patients with systemic sclerosis.. <i>Modern Rheumatology</i> , 2021 ,	3.3	0
30	Lupus Profundus and Discoid Lupus following a diagnosis of Kikuchi-Fujimoto Disease. <i>JAAD Case Reports</i> , 2021 ,	1.4	
29	Targeting the Preclinical Phase of Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , 2015 , 11, 711-3	0.7	2
28	Hydroxychloroquine in Dermatology and Beyond: Recent Update. <i>Indian Dermatology Online Journal</i> , 2020 , 11, 453-464	0.9	5
27	Prevalence of systemic lupus erythematosus-related symptoms assessed by using the Connective Tissue Disease Screening Questionnaire in a large population-based cohort. <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	0
26	Differentiating between UCTD and early-stage SLE: from definitions to clinical approach. <i>Nature Reviews Rheumatology</i> , 2021 ,	8.1	4
25	Controversies in Systemic Lupus Erythematosus: Are We Treating Our Patients Adequately?. <i>Journal of Clinical Rheumatology</i> , 2021 ,	1.1	1
24	Hydroxychloroquine in dermatology and beyond: Recent update. <i>Indian Dermatology Online Journal</i> , 2020 , 11, 453	0.9	10
23	Cutaneous Lupus. 2022 , 25-52		
22	Applying Early Intervention Strategies to Autoimmune Skin Diseases. Is the Window of Opportunity Preclinical? A Dermato-Rheumatology Perspective.. <i>Journal of Investigative Dermatology</i> , 2022 ,	4.3	0
21	Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge.. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022 , 14, 1759720X211073001	3.8	5
20	Autophagy and Skin Diseases.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 844756	5.6	0
19	The Role of Clinical Features and Serum Biomarkers in Identifying Patients with Incomplete Lupus Erythematosus at Higher Risk of Transitioning to Systemic Lupus Erythematosus: Current Perspectives.. <i>Journal of Inflammation Research</i> , 2022 , 15, 1133-1145	4.8	0
18	A Systematic Review of the Progression of Cutaneous Lupus to Systemic Lupus Erythematosus.. <i>Frontiers in Immunology</i> , 2022 , 13, 866319	8.4	1
17	Ontology-Based Classification and Analysis of Adverse Events Associated With the Usage of Chloroquine and Hydroxychloroquine.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 812338	5.6	0
16	Increase in Ca ²⁺ -Activated cAMP/PKA Signaling Prevents Hydroxychloroquine-Induced Bradycardia of the Cardiac Pacemaker. <i>Frontiers in Physiology</i> , 2022 , 13,	4.6	1
15	Collagen Vascular Disorders. 2016 , 509-539.e8		

14 Antimalarial agents. **2013**, 241-251.e3 3

13 Pre-Clinical Autoimmunity in Lupus Relatives: Self-Reported Questionnaires and Immune Dysregulation Distinguish Relatives Who Develop Incomplete or Classified Lupus From Clinically Unaffected Relatives and Unaffected, Unrelated Individuals. *Frontiers in Immunology*, **2022**, 13, 8.4 0

12 Understanding the Concept of Pre-Clinical Autoimmunity: Prediction and Prevention of Systemic Lupus Erythematosus: Identifying Risk Factors and Developing Strategies Against Disease Development. *Frontiers in Immunology*, 13, 8.4 2

11 Shame, Name, Give Up the Game? Three Approaches to Uncertainty. **2022**, 209-217

10 Preventing organ damage in systemic lupus erythematosus: the impact of early biological treatment. *Expert Opinion on Biological Therapy*, **2022**, 22, 821-829 5.4 1

9 Stress, mindfulness, and systemic lupus erythematosus: An overview and directions for future research. 096120332211229

8 Development of a child-friendly oral drug formulation using liposomal multilamellar vesicle technology. **2022**, 625, 122107

7 Predicting progression from undifferentiated connective tissue disease to definite connective tissue disease: A systematic review and meta-analysis. **2022**, 103184 1

6 The association between hydroxychloroquine use and future development of systemic lupus erythematosus in patients with primary Sjögren's syndrome. 0

5 Clinical characteristics, management, and quality of life of psoriasis patients with coexistent lupus erythematosus: Data from the Malaysian Psoriasis Registry. 0

4 Incomplete systemic lupus erythematosus: terminology, diagnosis, course and therapy. **2022**, 100, 447-455 0

3 Systemic Lupus Erythematosus May Be a Risk Factor for Antimalarial-Induced Retinopathy Compared With Other Rheumatologic Diseases. **2023**, 5, 173-179 0

2 Undifferentiated Connective Tissue Disease: Comprehensive Review. 0

1 The Rise and Rise of Lupus. 096120332311698 0